GlassScriptPhysician profile
Saul D Gorman
NPI 1982676045
$7,656.52
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,008 · 2020: $1,106 · 2021: $1,683 · 2022: $1,659 · 2023: $1,180 · 2024: $20.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,337.53 | 2019-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $869.08 | 2019-2023 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $811.70 | 2019-2023 | Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $734.83 | 2019-2023 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $711.25 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $656.29 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $522.91 | 2019-2023 | Ingrezza |
| Indivior INC. | $482.27 | 2019-2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $366.33 | 2020-2022 | |
| Allergan, INC. | $295.26 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $245.04 | 2019-2022 | |
| Lundbeck LLC | $243.25 | 2019-2023 | Abilify Maintena, Abilify Asimtufii |
| Merck Sharp & Dohme LLC | $128.38 | 2020-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $100.20 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.81 | 2020-2023 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $26.56 | 2022 | |
| Validus Pharmaceuticals LLC | $19.25 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.87 | 2020 | |
| Noven Therapeutics, LLC | $13.88 | 2020 | |
| Eisai INC. | $13.85 | 2021 | |
| Aytu Biopharma, INC. | $12.02 | 2019 | |
| Noven Pharmaceuticals, INC. | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Gorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.